Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
3/1/2000
1.
Phase II Pilot Study of Vaccination with Breast Cancer Mucin Peptide and Keyhole Limpet Hemocyanin plus the Immunologic Adjuvant QS21 for High-Risk Breast Cancer after Definitive Therapy: Stage I/II/IIIA with Rising Tumor Markers and Stage IIIB/IV (Summary Last Modified 03/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
no age specified
NCI
MSKCC-94130
NCI-H95-0628
Last Modified:
5/1/2002
 
First Published:
12/1/1999
2.
Phase II Study of Vaccination With Glycosylated MUC-1 Antigen With Keyhole Limpet Hemocyanin Conjugate Plus Immunological Adjuvant QS21 in Patients With High Risk Breast Cancer (Summary Last Modified 05/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
MSKCC-99023
NCI-H99-0043, NCT00004156
Last Modified:
5/1/1997
3.
Phase I Study of Vaccination with MUC-1-KLH Conjugate with the Immunologic Adjuvant QS21 for Recurrent Prostate Cancer (Summary Last Modified 05/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Other
MSKCC-96023
NCI-V96-0877
Last Modified:
5/1/2002
 
First Published:
5/1/2000
4.
Phase I Study of Vaccination With Glycosylated MUC-1 Antigen With Keyhole Limpet Hemocyanin Conjugate Plus Immunological Adjuvant QS21 in Patients With Prostate Cancer (Summary Last Modified 05/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
MSKCC-99040
NCI-G00-1773, NCT00005632
Last Modified:
10/1/2000
 
First Published:
7/1/2000
5.
Phase I Study of Glycosylated MUC-1-KLH Vaccine Plus Adjuvant QS21 in Patients With Ovarian, Fallopian Tube, or Peritoneal Epithelial Cancer (Summary Last Modified 10/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
MSKCC-99121
NCI-H00-0060, NCT00006041
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute